326 related articles for article (PubMed ID: 20028367)
1. Chronic alcohol consumption disrupted cholesterol homeostasis in rats: down-regulation of low-density lipoprotein receptor and enhancement of cholesterol biosynthesis pathway in the liver.
Wang Z; Yao T; Song Z
Alcohol Clin Exp Res; 2010 Mar; 34(3):471-8. PubMed ID: 20028367
[TBL] [Abstract][Full Text] [Related]
2. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
3. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
[TBL] [Abstract][Full Text] [Related]
4. [Electroacupuncture mitigates hyperlipidemia via improving cholesterol metabolism mediated by SCAP/SREBP-2 signaling in liver tissue in rats].
Wu H; Zhang ZQ; Chen L; Liao S; Wang XF; Lin W
Zhen Ci Yan Jiu; 2023 Apr; 48(4):325-30. PubMed ID: 37186195
[TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibitor treatment reduced fatty acid, triacylglycerol and cholesterol synthesis.
Oliva J; French SW; Li J; Bardag-Gorce F
Exp Mol Pathol; 2012 Aug; 93(1):26-34. PubMed ID: 22445925
[TBL] [Abstract][Full Text] [Related]
6. PCSK9 inhibition as a novel therapeutic target for alcoholic liver disease.
Lee JS; Mukhopadhyay P; Matyas C; Trojnar E; Paloczi J; Yang YR; Blank BA; Savage C; Sorokin AV; Mehta NN; Vendruscolo JCM; Koob GF; Vendruscolo LF; Pacher P; Lohoff FW
Sci Rep; 2019 Nov; 9(1):17167. PubMed ID: 31748600
[TBL] [Abstract][Full Text] [Related]
7. Kanglexin, a new anthraquinone compound, attenuates lipid accumulation by activating the AMPK/SREBP-2/PCSK9/LDLR signalling pathway.
Li X; Hu X; Pan T; Dong L; Ding L; Wang Z; Song R; Wang X; Wang N; Zhang Y; Wang J; Yang B
Biomed Pharmacother; 2021 Jan; 133():110802. PubMed ID: 33202286
[TBL] [Abstract][Full Text] [Related]
8. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
[TBL] [Abstract][Full Text] [Related]
9. Synergic hypocholesterolaemic effect of n-3 PUFA and oestrogen by modulation of hepatic cholesterol metabolism in female rats.
Oh Y; Jin Y; Park Y
Br J Nutr; 2015 Dec; 114(11):1766-73. PubMed ID: 26388416
[TBL] [Abstract][Full Text] [Related]
10. Chronic-binge ethanol feeding aggravates systemic dyslipidemia in
Hoebinger C; Rajcic D; Silva B; Hendrikx T
Front Endocrinol (Lausanne); 2023; 14():1148827. PubMed ID: 37560305
[TBL] [Abstract][Full Text] [Related]
11. Importance of proprotein convertase subtilisin/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors.
Persson L; Gälman C; Angelin B; Rudling M
Endocrinology; 2009 Mar; 150(3):1140-6. PubMed ID: 19008317
[TBL] [Abstract][Full Text] [Related]
12. The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis.
Mousavi SA; Berge KE; Leren TP
J Intern Med; 2009 Dec; 266(6):507-19. PubMed ID: 19930098
[TBL] [Abstract][Full Text] [Related]
13. Regulatory mechanism of mineral-balanced deep sea water on hypocholesterolemic effects in HepG2 hepatic cells.
Lee KS; Kwon YS; Kim S; Moon DS; Kim HJ; Nam KS
Biomed Pharmacother; 2017 Feb; 86():405-413. PubMed ID: 28012395
[TBL] [Abstract][Full Text] [Related]
14. Chitosan oligosaccharides enhance lipid droplets via down-regulation of PCSK9 gene expression in HepG2 cells.
Yang X; Zhang J; Chen L; Wu Q; Yu C
Exp Cell Res; 2018 May; 366(2):152-160. PubMed ID: 29548750
[TBL] [Abstract][Full Text] [Related]
15. Aloe-emodin exerts cholesterol-lowering effects by inhibiting proprotein convertase subtilisin/kexin type 9 in hyperlipidemic rats.
Su ZL; Hang PZ; Hu J; Zheng YY; Sun HQ; Guo J; Liu KY; Du ZM
Acta Pharmacol Sin; 2020 Aug; 41(8):1085-1092. PubMed ID: 32203084
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of proprotein convertase subtilisin/kexin type 9: a novel mechanism of berberine and 8-hydroxy dihydroberberine against hyperlipidemia.
Liu DL; Xu LJ; Dong H; Chen G; Huang ZY; Zou X; Wang KF; Luo YH; Lu FE
Chin J Integr Med; 2015 Feb; 21(2):132-8. PubMed ID: 24893659
[TBL] [Abstract][Full Text] [Related]
17. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver.
Park SW; Moon YA; Horton JD
J Biol Chem; 2004 Nov; 279(48):50630-8. PubMed ID: 15385538
[TBL] [Abstract][Full Text] [Related]
18. Activation of mTORC1 disrupted LDL receptor pathway: a potential new mechanism for the progression of non-alcoholic fatty liver disease.
Liu J; Ma KL; Zhang Y; Wu Y; Hu ZB; Lv LL; Tang RN; Liu H; Ruan XZ; Liu BC
Int J Biochem Cell Biol; 2015 Apr; 61():8-19. PubMed ID: 25622557
[TBL] [Abstract][Full Text] [Related]
19. Proprotein convertase subtilisin/kexin type 9 expression is transiently up-regulated in the acute period of myocardial infarction in rat.
Zhang Y; Liu J; Li S; Xu RX; Sun J; Tang Y; Li JJ
BMC Cardiovasc Disord; 2014 Dec; 14():192. PubMed ID: 25519174
[TBL] [Abstract][Full Text] [Related]
20. Light-to-moderate ethanol feeding augments AMPK-α phosphorylation and attenuates SREBP-1 expression in the liver of rats.
Nammi S; Roufogalis BD
J Pharm Pharm Sci; 2013; 16(2):342-51. PubMed ID: 23958203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
